Menu
Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 17
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone [Corrigendum]
Authors Price DB , Henley W, Cançado JED , Fabbri LM , Kerstjens HA , Papi A , Roche N , Şen E, Singh D, Vogelmeier CF, Barille S, Nudo E, Carter V, Skinner D , Vella R , Georges G
Received 24 February 2022
Accepted for publication 24 February 2022
Published 7 March 2022 Volume 2022:17 Pages 489—490
Price DB, Henley W, Cançado JED, et al. Int J Chron Obstruct Pulmon Dis. 2022;17:355–370
On page 356, last paragraph of the Introduction section, the paragraph should be corrected from “ …Collectively, there is a requirement for a real- world study comparing the use of extrafine particle fixed dose combination beclometasone dipropionate (ef-FDC-BDP; with a MMAD of 1.1μm in FOSTER® and TRIMBOW® NEXTHALER® DPIs and 1.3μm in FOSTER® pMDI) with other ICSs, such as fine particle fluticasone (fp-FDC-F; with a MMAD of 3.9μm and 3.2μm for propionate (SERETIDE® DISKUS®) and furoate (RELVAR® ELLIPTA®) esters respectively).21–23 to “ …Collectively, there is a requirement for a real-world study comparing the use of extrafine particle fixed dose combination beclometasone dipropionate (ef-FDC-BDP; with a MMAD of 1.1µm in TRIMBOW® pMDI and 1.3µm in FOSTER® pMDI) with other ICSs, such as fine particle fluticasone (fp-FDC-F; with a MMAD of 3.9µm and 3.2µm for propionate (SERETIDE® DISKUS®) and furoate (RELVAR® ELLIPTA®) esters respectively).21-23
The authors apologize for this error and advise they do not affect the results of the paper.
© 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.